Randomized, Placebo-Controlled Trial of N-acetylcysteine In Parkinson's Disease Patients: A Pilot Study

Summary

This is a study on Parkinson's disease patients, referred to Tohid Hospital of Sanandaj City. The patients receive N-acetylcysteine for one year. The efficacy of the Drug is evaluated based on clinical interview, filling Unified Parkinson's Disease Rating Scale (UPDRS) questionnaire, and single-photon emission computerized tomography (SPECT) brain imaging. The only person who has not been blinded for the study is the supplier of the drug and placebo. Inclusion criteria: Patient's informed consent Exclusion criteria: Having brain surgery within a year before the initiation of the intervention. Medication group: receiving 1200 mg N-acetylcysteine per day, twice daily, each time 600 mg. placebo group: receiving a placebo with similar appearance, color, odor, and taste like real medication.

Timeline

Start

2018-04-09

Primary completion

2021-12-22

Completion

2021-12-22

Drugs

Indications